- Home
- APVO vs FTFT Comparison
APVO vs FTFT Comparison
Compare APVO & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- FTFT
- Stock Information
- Founded
- APVO 2016
- FTFT N/A
- Country
- APVO United States
- FTFT United States
- Employees
- APVO N/A
- FTFT N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- FTFT Business Services
- Sector
- APVO Health Care
- FTFT Consumer Discretionary
- Exchange
- APVO Nasdaq
- FTFT Nasdaq
- Market Cap
- APVO 4.1M
- FTFT 3.9M
- IPO Year
- APVO N/A
- FTFT N/A
- Fundamental
- Price
- APVO $4.95
- FTFT $1.17
- Analyst Decision
- APVO Strong Buy
- FTFT
- Analyst Count
- APVO 1
- FTFT 0
- Target Price
- APVO $5,920.00
- FTFT N/A
- AVG Volume (30 Days)
- APVO 393.8K
- FTFT 154.6K
- Earning Date
- APVO 05-14-2025
- FTFT 05-20-2025
- Dividend Yield
- APVO N/A
- FTFT N/A
- EPS Growth
- APVO N/A
- FTFT N/A
- EPS
- APVO N/A
- FTFT N/A
- Revenue
- APVO N/A
- FTFT $2,031,913.00
- Revenue This Year
- APVO N/A
- FTFT N/A
- Revenue Next Year
- APVO N/A
- FTFT N/A
- P/E Ratio
- APVO N/A
- FTFT N/A
- Revenue Growth
- APVO N/A
- FTFT N/A
- 52 Week Low
- APVO $4.30
- FTFT $1.06
- 52 Week High
- APVO $658.60
- FTFT $7.77
- Technical
- Relative Strength Index (RSI)
- APVO 28.32
- FTFT 35.84
- Support Level
- APVO $4.30
- FTFT $1.46
- Resistance Level
- APVO $5.18
- FTFT $1.57
- Average True Range (ATR)
- APVO 1.22
- FTFT 0.14
- MACD
- APVO 0.72
- FTFT -0.04
- Stochastic Oscillator
- APVO 6.47
- FTFT 15.07
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and cryptocurrency mining farm in the U.S. The company's reportable segments include the Supply chain financing/trading segment which generates key revenue, and the Asset management service segment.